IQWiG has published its benefit assessments of Boehringer Ingelheim's nerandomilast (Jascayd), and the verdicts differ by indication. In idiopathic pulmonary fibrosis (IPF) it found added benefit not proven. In progressive pulmonary fibrosis (PPF) it saw an indication of minor added benefit, but only for patients already on nintedanib. The G-BA decision is due in early February 2027.
Two procedures, one product
The EU authorised Jascayd on 15 July 2026 for adults with IPF and adults with PPF, after a CHMP opinion on 21 May 2026. The G-BA opened two separate AMNOG (early benefit assessment) procedures on 15 August 2026: one for IPF and one for PPF excluding IPF.
The comparators differ. For IPF the G-BA's appropriate comparator therapy is pirfenidone or nintedanib. For PPF it is nintedanib. Both are provisional: the binding determination comes only with the benefit decision.
What IQWiG concluded
In IPF, IQWiG's dossier assessment rates nerandomilast as an add-on to existing nintedanib or pirfenidone therapy as "added benefit not proven". For newly initiated pirfenidone or nintedanib, or for monotherapy, it also finds added benefit not proven, and notes that no suitable data were available.
In PPF, the verdict splits. As an add-on to existing nintedanib therapy, IQWiG sees an "Anhaltspunkt" (indication) of minor added benefit. For newly initiated nintedanib or monotherapy, added benefit is not proven, again for lack of suitable data.
The IQWiG report for IPF is built on the FIBRONEER-IPF trial, analysed in the subpopulation on antifibrotic background therapy. That matters because the efficacy behind the EU licence was measured against placebo. In the IPF study the EMA reports a one-year FVC decline of about 115 ml on 18 mg twice daily and about 139 ml on 9 mg twice daily, against about 183 ml on placebo. In the PPF study the declines were about 99 ml and 85 ml, against about 166 ml on placebo. A placebo-controlled result and a comparator-based AMNOG verdict answer different questions.
Why the subgroups decide the outcome
- The comparator defines the population. Because the G-BA's comparators are active antifibrotics, only the part of a trial that matches the comparator can inform the assessment. IQWiG found no suitable data for newly initiated therapy or monotherapy.
- Background therapy splits one trial into several verdicts. The same product received "not proven" and "minor" within one indication, depending on whether patients were already on nintedanib.
- A positive licence trial does not carry over. The EMA's placebo-controlled FVC results did not translate into a proven benefit in IPF.
What happens next
These are IQWiG's assessments, not the G-BA's decision. Written comments are open until 7 December 2026, the oral hearing is on 21 December 2026, and IQWiG's page notes that the comment procedure can change the assessment. Boehringer Ingelheim and clinical experts can add data and argument on subgroups, and the G-BA can reach a different rating.
What it means for market access teams
- Plan subgroups before the pivotal trial reads out. If the comparator is an active drug that many patients already take, background-therapy subpopulations need prespecified analyses, not post hoc cuts.
- Cover the patients who are not on the comparator. "No suitable data" for newly initiated therapy and monotherapy is a dossier gap, and it can sit alongside a strong licence trial.
- Expect the price negotiation to follow the weakest subgroup. A split rating complicates the GKV-SV negotiation and the share of patients each rating covers.
To discuss how comparator choice and subgroup design affect your AMNOG dossier, get in touch.